Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 126
---
 initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions,                                                                      
 including failure to receive regulatory approval of our drug to market for our product candidates; |

66

| ● | adverse developments concerning 
 our manufacturers;              |

| ● | our inability to obtain adequate                                                 
 product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish 
 collaborations, if needed; |

| ● | our failure to commercialize 
 our product candidates;      |

| ● | additions or departures of              
 key scientific or management personnel; |

| ● | unanticipated serious safety                           
 concerns related to the use of our product candidates; |

| ● | introduction of new drugs by 
 our competitors;             |

| ● | announcements of significant                                                                          
 acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change in our 
 management;                   |

| ● | our ability to effectively 
 manage our growth;         |

| ● | the size and growth of our 
 initial target markets;    |

| ● | actual or anticipated variations 
 in quarterly operating results;  |

| ● | our cash position; |

| ● | our failure to meet the estimates                                                           
 and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response                                                                                       
 to press releases or other public announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research reports                                                                                                             
 about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of research coverage 
 by securities analysts;                                                                                                                     |

| ● | guidance, if any, that we provide                                                 
 to the public, any changes in this guidance or our failure to meet this guidance; |

| ● | changes in the market valuations 
 of similar companies;            |

| ● | overall performance of the 
 equity markets;            |

| ● | sales of our Common Stock by           
 us or our stockholders, in the future; |

| ● | trading volume of our Common 
 Stock;                       |

| ● | investor perceptions of the                                                                        
 investment opportunity associated with our Common Stock relative to other investment alternatives; |

67

| ● | actions by institutional or 
 activist stockholders;      |

| ● | change in accounting standards,                      
 policies, guidelines, interpretations or principles; |

| ● | ineffectiveness of our internal 
 controls;                       |